Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
Titel:
Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
Auteur:
Cortes Castan, J. Schmid, P. Awada, A. Uppal, H. Tudor, I.C. Blaney, M.E. Steinberg, J.L. Yardley, D.A. Hudis, C. Traina, T.A.